Transthyretin Gene Silencing in Amyloid Transthyretin Cardiomyopathy: A Novel Treatment Delivers New Dilemmas
- PMID: 40380963
- DOI: 10.1016/j.jacc.2025.04.015
Transthyretin Gene Silencing in Amyloid Transthyretin Cardiomyopathy: A Novel Treatment Delivers New Dilemmas
Keywords: HELIOS-B trial; RNA interference; heart failure; transthyretin cardiac amyloidosis; vutrisiran.
Conflict of interest statement
Funding Support and Author Disclosures Dr Cuddy has received grant support from the National Institutes of Health (grant 1K23HL166686-01) and the American Heart Association (grant 23CDA857664); and has received personal (speaking/consulting) fees from Pfizer, Bridgebio, Ionis, AstraZeneca, Alexion, Novo-Nordisk, Life Molecular Imaging, and Attralus. Dr Ambardekar has reported that he has no relationships relevant to the contents of this paper to disclose.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
